As the summer winds down, HDA is hard at work planning our 2018 Traceability Seminar, which will take place three weeks earlier, on October 17–19 at the Renaissance Washington, DC Downtown Hotel. As the industry passes the halfway mark for DSCSA implementation, our 2018 agenda leverages HDA and our members’ unique expertise to help fellow stakeholders answer critical questions while planning for the multiple milestones ahead.
On February 28, FDA hosted its third and final public meeting in a series focused on "Enhanced Drug Distribution Security Under the Drug Supply Chain Security Act [DSCSA],” bringing together a broad group of stakeholders, including manufacturers, distributors, dispensers, hospitals and service providers.
In an opinion piece published today in the Capitol Hill newspaper, The Hill, HDA and NACDS called on members of Congress to honor its commitment to protecting patients and the safety of the supply chain by rejecting any proposal that would call for the importation of prescription drugs from foreign markets.
HDA President and CEO John M. Gray has outlined the organization’s priorities for the upcoming year in his annual “Pharmacy Outlook” column, published in the January 2 issue of Chain Drug Review.